Pyelonephritis-Pipeline Review, H1 2015

Pyelonephritis-Pipeline Review, H1 2015

  • Products Id :- GMDHC6100IDB
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Pyelonephritis-Pipeline Review, H1 2015


Global Markets Direct's, 'Pyelonephritis-Pipeline Review, H1 2015', provides an overview of the Pyelonephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pyelonephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pyelonephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Pyelonephritis

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Pyelonephritis and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Pyelonephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Pyelonephritis pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Pyelonephritis

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Pyelonephritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Pyelonephritis Overview 6

Therapeutics Development 7

Pipeline Products for Pyelonephritis-Overview 7

Pipeline Products for Pyelonephritis-Comparative Analysis 8

Pyelonephritis-Therapeutics under Development by Companies 9

Pyelonephritis-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Pyelonephritis-Products under Development by Companies 12

Pyelonephritis-Companies Involved in Therapeutics Development 13

Achaogen Inc. 13

AstraZeneca PLC 14

Merck & Co., Inc. 15

MerLion Pharmaceuticals Pte Ltd 16

The Medicines Company 17

Pyelonephritis-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 27

(ceftazidime + avibactam)-Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

(meropenem+ RPX-7009)-Drug Profile 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

finafloxacin-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

plazomicin sulfate-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

relebactam-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Pyelonephritis-Recent Pipeline Updates 37

Pyelonephritis-Dormant Projects 42

Pyelonephritis-Discontinued Products 43

Pyelonephritis-Product Development Milestones 44

Featured News & Press Releases 44

May 15, 2012: Achaogen Provides Update On Phase II Study Of Plazomicin 44

Appendix 45

Methodology 45

Coverage 45

Secondary Research 45

Primary Research 45

Expert Panel Validation 45

Contact Us 46

Disclaimer 46

List of Tables

Number of Products under Development for Pyelonephritis, H1 2015 7

Number of Products under Development for Pyelonephritis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Late Stage Development, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Pyelonephritis-Pipeline by Achaogen Inc., H1 2015 13

Pyelonephritis-Pipeline by AstraZeneca PLC, H1 2015 14

Pyelonephritis-Pipeline by Merck & Co., Inc., H1 2015 15

Pyelonephritis-Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2015 16

Pyelonephritis-Pipeline by The Medicines Company, H1 2015 17

Assessment by Monotherapy Products, H1 2015 18

Assessment by Combination Products, H1 2015 19

Number of Products by Stage and Target, H1 2015 21

Number of Products by Stage and Mechanism of Action, H1 2015 23

Number of Products by Stage and Route of Administration, H1 2015 25

Number of Products by Stage and Molecule Type, H1 2015 26

Pyelonephritis Therapeutics-Recent Pipeline Updates, H1 2015 37

Pyelonephritis-Dormant Projects, H1 2015 42

Pyelonephritis-Discontinued Products, H1 2015 43

List of Figures

Number of Products under Development for Pyelonephritis, H1 2015 7

Number of Products under Development for Pyelonephritis-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products by Top 10 Targets, H1 2015 20

Number of Products by Stage and Top 10 Targets, H1 2015 21

Number of Products by Top 10 Mechanism of Actions, H1 2015 22

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23

Number of Products by Top 10 Routes of Administration, H1 2015 24

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25

Number of Products by Stage and Top 10 Molecule Types, H1 2015 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Achaogen Inc.

AstraZeneca PLC

Merck & Co., Inc.

MerLion Pharmaceuticals Pte Ltd

The Medicines Company

Pyelonephritis Therapeutic Products under Development, Key Players in Pyelonephritis Therapeutics, Pyelonephritis Pipeline Overview, Pyelonephritis Pipeline, Pyelonephritis Pipeline Assessment

select a license
Single User License
USD 2000 INR 143580
Site License
USD 4000 INR 287160
Corporate User License
USD 6000 INR 430740



I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]